Editorial: Pfizer plan to market torcetrapib only with Lipitor sets bad precedent

03/15/2005 | NYTimes.com

Pfizer's plan to market its complementary statin drug only in combination with its Lipitor, denying alternatives for patients who might need them, is "a terrible precedent" for the drug industry, The New York Times editorial says. Torcetrapib is still in trial, but by tying it to Lipitor, the company will be able to extend the Lipitor patent and, in combination, create a blockbuster bigger than Lipitor.

View Full Article in:

NYTimes.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC